Acumen pharmaceuticals, inc. ABOS.US Overview
BetaUS StockHealthcare
(No presentation for ABOS)
ABOS AI Analysis & Strategy
Analysis Conclusion
The stock has a low value rating. If your investment strategy is value-oriented and you have long-term positions, it's crucial to adhere to your exit plan and consider reducing holdings.
ABOS Current Performance
-7.44%
Acumen pharmaceuticals, inc.
-1.19%
Avg of Sector
0.52%
S&P500
ABOS Key Information
ABOS Financial Forecast
Unit : USD
ABOS Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -0.29 | - | 0% | 290K | - | -98.1% | - |
ABOS Profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.